Design of Phase Three of KYSA-6, a Global Open-label, Randomized, Controlled Study of KYV-101, a Fully Human CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, Versus Ongoing Standard-of-Care (SOC) Immunosuppressive Therapy in Generalized Myasthenia Gravis (gMG) (P9-9.011)

Sri Mupiddi; Michael C. Hunter; Sarah Hoffmann; Tobias Hegelmaier; Jeremias Motte; R Gold; Dimitrios Mougiakakos; Charlotte Schubert; Stefanie Schreiber; Ali Habib; Christian Geis; Olimpia Carbunar; Sheetal Shroff; Marinos Dalakas; Achim Berthele; Perry Shieh; Alexandru Barboi; Livia Dutra; Alanood Alsolaihim; Edward Needham; Fiona Norwood; Gary Cutter; Brad Hunter; Justin Chou; Baodong Xing; Dominic Borie; N. Gehchan; Aiden Haghikia

doi:10.1212/wnl.0000000000212823

Key Points

The aim is to assess the efficacy of KYV-101 compared to ongoing standard-of-care treatment in patients with generalized myasthenia gravis.
Global open-label design
Randomized controlled trial
Comparative analysis with standard-of-care treatment
Efficacy outcomes to be measured against standard-of-care treatment
Expected improved outcomes with KYV-101 therapy
Comparison aims to establish benefits over existing treatment options

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized trial assesses efficacy of KYV-101 versus standard-of-care in generalized myasthenia gravis, suggesting potential benefits of novel therapy.

Abstract

Assess the efficacy of KYV-101 in generalized myasthenia gravis (gMG) compared with standard-of-care (SOC) treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mupiddi et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f056188 https://doi.org/10.1212/wnl.0000000000212823

View at Publisher

Ask AI

Bookmark

Share

Design of Phase Three of KYSA-6, a Global Open-label, Randomized, Controlled Study of KYV-101, a Fully Human CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, Versus Ongoing Standard-of-Care (SOC) Immunosuppressive Therapy in Generalized Myasthenia Gravis (gMG) (P9-9.011)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Design of Phase Three of KYSA-6, a Global Open-label, Randomized, Controlled Study of KYV-101, a Fully Human CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, Versus Ongoing Standard-of-Care (SOC) Immunosuppressive Therapy in Generalized Myasthenia Gravis (gMG) (P9-9.011)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading